Project Grant R01HL187343
Award Date 8/15/26
Completion Date 5/31/31
Dollars Obligated $661K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Baylor College of Medicine $647,803 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of intestinal stem cell epigenome in gastrointestinal graft-versus-host disease (GI GVHD). The research targets epigenetic modifications in intestinal stem cells (ISCs) as a therapeutic mechanism to mitigate GI GVHD, the most severe complication of allogeneic hematopoietic cell transplantation. The...
- The National Heart Lung and Blood Institute awarded Sloan-Kettering Institute For Cancer Research $281,722 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a rationally designed oral live biotherapeutic product (LBP) that delivers a defined composition of pure bacterial strains to modulate the gastrointestinal microbiome for treating acute graft-versus-host disease (AGVHD) following allogeneic hematopoietic cell transplantation. The research addresses...
- The National Heart, Lung, and Blood Institute awarded $1,577,069 to the Regents of the University of Minnesota on June 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop novel therapies for chronic graft-versus-host disease fibrosis using murine models and state-of-the-art molecular techniques. The award funds research into the pathobiology of chronic graft-versus-host disease (CGVHD), specifically investigating how T cell and B cell engagement initiates disease...
- The National Heart, Lung, and Blood Institute awarded The Medical College of Wisconsin, Inc. $675,405 on June 15, 2026, under CFDA 93.837 (Cardiovascular Diseases Research) to conduct research on augmenting regulatory T cell reconstitution during graft versus host disease (GVHD). The project runs through April 30, 2030, with work performed in Wauwatosa, Wisconsin. The research addresses GVHD, the major complication of allogeneic hematopoietic stem cell transplantation, by examining the...
- Federal Project Grant Award Summary The Medical College of Wisconsin, Inc. received a $151,092 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective August 1, 2025, through July 31, 2030. This five-year research initiative focuses on investigating macrophage polarization and function in graft-versus-host disease (GVHD), a major complication of allogeneic hematopoietic stem cell transplantation...
- The National Heart, Lung, and Blood Institute of the Department of Health and Human Services awarded The Johns Hopkins University $379,509 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop mesenchymal stem cell (MSC) therapies with enhanced immunosuppressive efficacy for graft-versus-host disease treatment through mechanical programming of cell microenvironments. The research focuses on identifying and providing optimal mechanical cues during MSC...
- The National Institute of Allergy and Infectious Diseases awarded Purdue University $775,740 on June 24, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the differentiation, fate, and function of pathogenic T helper cells in graft-versus-host disease (GVHD). GVHD occurs in approximately 30–70% of individuals receiving hematopoietic cell transfer for cancer immunotherapy. Intestinal inflammation in GVHD is characterized by recruitment of CD4 T...
- The National Institute of Allergy and Infectious Diseases awarded $436,454 to Massachusetts General Hospital on February 6, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate gastrointestinal tract-driven T cell reprogramming during acute graft-versus-host disease (AGVHD). The recipient will conduct research across three specific aims examining how the gastrointestinal tract drives systemic alloimmunity in patients after allogeneic hematopoietic cell...
- The National Heart, Lung, and Blood Institute awarded Baylor College of Medicine $240,707 on May 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate mechanisms of marginal zone B cell depletion in sickle cell disease spleen tissue. The research addresses adaptive immune dysfunction in sickle cell disease, a genetic hemolytic anemia affecting millions worldwide. Prior K23 award work identified an age-related decline in unswitched memory B cells in children...
- The National Heart, Lung, and Blood Institute awarded Baylor College of Medicine $158,892 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to examine the impact of DNMT3A protein reduction on normal and clonal hematopoiesis. The research investigates mechanisms by which somatic DNMT3A mutations drive clonal hematopoiesis—the clonal expansion of mutated hematopoietic stem and progenitor cells—which accelerates with age and increases the risk of hematologic...